CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| AALL0331 | COG | Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL): A Phase III Group-Wide Study | Pediatric CIRB | Completed |
| ACNS0423 | COG | A Phase II Study of Concurrent Radiation and Temozolomide Followed by Temozolomide and Lomustine (CCNU) in the Treatment of Children with High Grade Glioma: An Intergroup Study for Participation by COG and the Dutch Childhood Oncology Group - SKION (Stichting Kinderoncologie Nederland) | Pediatric CIRB | Completed |
| ARET2121 | COG | Intravitreal Melphalan for Intraocular Retinoblastoma | Pediatric CIRB | Available to Open |
| AALL1331 | COG | Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467; NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL): A Groupwide Phase III Study | Pediatric CIRB | Available to Open |
| PBTC-053 | PBTC | A Pediatric Brain Tumor Consortium Phase I/II and Surgical Study of CX-4945 in Patients with Recurrent SHH Medulloblastoma | Pediatric CIRB | Available to Open |
| ANBL1221 | COG | A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864; IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 764038; IND# 4308) in Children with Refractory; Relapsed or Progressive Neuroblastoma | Pediatric CIRB | Completed |
| ADVL06B1 | COG | A Pharmacokinetic-Pharmacodynamic-Pharmacogenetic Study of Actinomycin-D and Vincristine in Children with Cancer: A Group-Wide Non-Therapeutic Study | Pediatric CIRB | Completed |
| ADVL1515 | COG | A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors | Pediatric CIRB | Completed |
| AREN0532 | COG | Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor: A Groupwide Phase III Study | Pediatric CIRB | Available to Open |
| ARST0921 | COG | A Randomized Phase II Trial of Bevacizumab (IND# 7921; Avastin) and Temsirolimus (IND# 61010; Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma: A Groupwide Phase II Study | Pediatric CIRB | Completed |